RESUMO
Acute chest syndrome (ACS) is a leading cause of morbimortality in sickle cell disease (SCD). In this prospective observational study, we investigated sputum interleukin-6 (IL-6) level as an ACS severity marker during 30 ACS episodes in 26 SCD children. Sputum IL-6 levels measured within the first 72 h of hospitalisation for ACS were significantly higher in patients with oxygen requirement ≥2 L/min, ventilation (invasive and/or non-invasive) length ≥5 days, bilateral and/or extensive opacities on chest X-ray or erythrocytapheresis requirement. Sputum IL-6 could serve as an ACS severity marker to help identify patients requiring targeted anti-inflammatory treatments such as tocilizumab.
RESUMO
Here, we report a dramatic efficacy of cannabidiol in an adolescent with SCD suffering from chronic pain refractory to other analgesics, with complete regression of chronic pain and rapid plasma histamine level normalization after treatment.
Assuntos
Síndrome Torácica Aguda , Anemia Falciforme , Hemoglobinopatias , Humanos , Criança , Interleucina-6 , Prognóstico , Estudos Prospectivos , EscarroRESUMO
We report a significant cluster of SARS-CoV-2 (B.1.617.2 variant) among young healthcare workers (HCW) (median age of 27years) living in the Mamoudzou interns apartment complex, belonging to the Hospital Center in Mayotte. Among them, 18 developed SARS-CoV-2 infection (62.1%) and all were symptomatic. The infection rate was higher for people who had had a second dose more than 6 months before than for those who had had a second dose less than 6 months before (P=0.05). This epidemic had no individual consequence, but the hospital functioning in Mayotte was significant impacted. This report reinforces the need for a third dose of vaccine among HCWs, in addition to non-pharmaceutical measures.